Rimifin 20 mg Tablets for Dogs

Country: Bretland

Tungumál: enska

Heimild: VMD (Veterinary Medicines Directorate)

Virkt innihaldsefni:

Carprofen

Fáanlegur frá:

Chanelle Pharmaceuticals Manufacturing Ltd

ATC númer:

QM01AE91

INN (Alþjóðlegt nafn):

Carprofen

Lyfjaform:

Tablet

Gerð lyfseðils:

POM-V - Prescription Only Medicine – Veterinarian

Meðferðarhópur:

Dogs

Lækningarsvæði:

Anti Inflammatory NSAID

Leyfisstaða:

Authorized

Leyfisdagur:

2007-11-08

Vara einkenni

Revised: March 2012
AN: 01175/2010
Page 1 of 7
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Rimifin 20 mg Tablets for dogs
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
ACTIVE INGREDIENT
Carprofen
20.0 mg/tablet
EXCIPIENTS
For a full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
A plain round flat bevelled edge white tablet with a breakline on one
side.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dogs.
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Reduction of inflammation and pain caused by musculo-skeletal
disorders and
degenerative
joint
disease.
As
a
follow
up
to
parenteral
analgesia
in
the
management of post-operative pain following soft tissue surgery.
4.3
CONTRA-INDICATIONS
Do not use in cats.
Do not use in case of hypersensitivity to active substance or to any
of the
excipients.
Do not use in dogs suffering from cardiac, hepatic or renal disease,
where there is
a possibility of gastro-intestinal ulceration or bleeding, or where
there is evidence of
a blood dyscrasia.
Refer to section 4.7.
Revised: March 2012
AN: 01175/2010
Page 2 of 7
4.4
SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to Sections 4.3 and 4.5
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Use in dogs less than 6 weeks of age, or in aged dogs, may involve
additional risk.
If such a use cannot be avoided, dogs may require careful clinical
management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a
potential risk of increased renal toxicity.
Concurrent administration of potential nephrotoxic drugs should be
avoided.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of
inflammatory conditions associated with bacterial infection,
appropriate concurrent
antimicrobial therapy should be instigated.
Do not administer other NSAIDs concurrently or within 24 hours of each
other.
Some NSAIDs may be highly bound to plasma proteins and compete with
other
highly bound drugs, which can lead to toxic effects.
SPECIAL PRECAUTIO